- Home
- ETS vs BCTX Comparison
ETS vs BCTX Comparison
Compare ETS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETS
- BCTX
- Stock Information
- Founded
- ETS 2020
- BCTX 2014
- Country
- ETS United States
- BCTX Canada
- Employees
- ETS N/A
- BCTX N/A
- Industry
- ETS Trucking Freight/Courier Services
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- ETS Industrials
- BCTX Health Care
- Exchange
- ETS Nasdaq
- BCTX Nasdaq
- Market Cap
- ETS 15.4M
- BCTX 14.4M
- IPO Year
- ETS 2025
- BCTX N/A
- Fundamental
- Price
- ETS $0.88
- BCTX $8.47
- Analyst Decision
- ETS
- BCTX Strong Buy
- Analyst Count
- ETS 0
- BCTX 1
- Target Price
- ETS N/A
- BCTX $40.00
- AVG Volume (30 Days)
- ETS 3.2M
- BCTX 103.8K
- Earning Date
- ETS 01-01-0001
- BCTX 10-28-2025
- Dividend Yield
- ETS N/A
- BCTX N/A
- EPS Growth
- ETS N/A
- BCTX N/A
- EPS
- ETS N/A
- BCTX N/A
- Revenue
- ETS $2,542,395.00
- BCTX N/A
- Revenue This Year
- ETS N/A
- BCTX N/A
- Revenue Next Year
- ETS N/A
- BCTX N/A
- P/E Ratio
- ETS N/A
- BCTX N/A
- Revenue Growth
- ETS 0.74
- BCTX N/A
- 52 Week Low
- ETS $0.86
- BCTX $6.00
- 52 Week High
- ETS $4.23
- BCTX $294.00
- Technical
- Relative Strength Index (RSI)
- ETS N/A
- BCTX 45.54
- Support Level
- ETS N/A
- BCTX $7.28
- Resistance Level
- ETS N/A
- BCTX $8.52
- Average True Range (ATR)
- ETS 0.00
- BCTX 0.71
- MACD
- ETS 0.00
- BCTX 0.67
- Stochastic Oscillator
- ETS 0.00
- BCTX 95.00
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.